Cases & Deals

  • Home
  • Practices
  • BioTheryX establishes patent portfolio for anti-hematological malignancy therapies

Share

BioTheryX establishes patent portfolio for anti-hematological malignancy therapies

May 2010

Client(s) BioTheryX, Inc.

Jones Day assists BioTheryX, Inc. in the development of a global patent portfolio related to small molecule drugs for the treatment of hematological malignancies.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.